Cardiol Therapeutics Inc.
CRDLHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cardiol Therapeutics Inc. (CRDL) is listed under Drug Manufacturers - Specialty & Generic. The $136.1M market capitalization puts CRDL squarely in micro-cap range for its industry. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Market Cap
$136.1M
Beta
0.72
P/E (TTM)
—
P/E (Fwd)
-4.81
EPS (TTM)
$-0.24
EPS (Fwd)
$-0.23
ROE
-190.2%
ROA
-90.9%
Cash
$26.1M
Total Debt
$106,998
Free CF
-$15.5M
52W Change
-5.9%
Annual Financials
Cash vs Debt
Where CRDL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRDL finished 20.86% below its 150-day moving average ($1.39) and 15.38% below its 200-day moving average ($1.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRDL overbought or oversold?
At the October 20, 2026 close, CRDL's RSI(14) was 6.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $26.1M in cash comfortably exceeding the $107K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$15.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -190.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CRDL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.